Back to Journals » Biologics: Targets and Therapy » Volume 6

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Total article views   HTML views PDF downloads Totals
14,498 Dovepress* 10,689+ 2,496 13,185
PubMed Central* 3,809 1,165 4,974
Totals 14,498 3,661 18,159
*Since 25 September 2012
+Since July 2016

View citations on PubMed Central and Google Scholar